Veniti

United States
Clintonville, Wisconsin, United States, 94538

Company profile

Veniti company profile

VENITI is the first medical device company developing a suite of innovative technology and solutions that will provide comprehensive treatment across the venous disease continuum. Venous disease refers to all conditions related to or caused by veins that become diseased or abnormal. This encompasses a broad set of maladies. The venous disease cycle begins when vein walls become weak or damaged, or the valves are stretched or injured, and can no longer prevent reflux (backward flow of blood). Once the veins lose their ability to convey blood without reflux, the progressive venous disease cycle has begun. This is commonly referred to as chronic venous insufficiency, or CVI. The blood will begin to back up into the peripheral veins, causing venous hypertension, potential thrombosis (clotting), and leading to even more damage of the vein walls and valves. This in turn leads to more reflux. The VENITI team of experts in science, technology and business are currently developing the VENITI VICI VENOUS STENT® System. Through this, and other, innovative technology, VENITI will achieve results that sets it apart in addressing the challenges specific to the venous system and venous disease.

Business identity

Contact email
[email protected]
Phone number
(314) 282-3753
Operating status
Closed
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2010-01-01, Year

Headquarters

Postal code
94538
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
5
Total equity funding
$65.2M
Last funding
Series D / $25M / 2016-09-08
Last equity funding
Series D / $25M
Investors
12
Lead investors
5
Founders
1
Articles
4
Closed on
2018-08-08
Exited on
2018-08-08

Founders and investors

Founders

Sean Morris

Lead investors

Baird CapitalHambrecht & Quist Capital ManagementLife Sciences Alternative FundingTekla Capital ManagementVectis Healthcare & Life Sciences Fund II

Investors

Baird CapitalCultivation CapitalProlog VenturesTekla Capital ManagementVolcano Capital